Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BZ-Oligo (Beijing BZ-Oligo Biotechnology Co., Ltd.) is a specialized biotechnology company focused on the synthesis and development of high-quality oligonucleotides and related reagents. The company provides a comprehensive suite of services, including custom DNA and RNA synthesis, modified oligonucleotides, and fluorescently labeled probes for research and diagnostic applications. BZ-Oligo also manufactures and supplies critical chemical components such as phosphoramidites and solid supports used in automated synthesis. Serving a global clientele of academic institutions and pharmaceutical companies, the firm plays a vital role in supporting molecular biology research and the development of nucleic acid-based therapeutics. Their expertise in complex chemical modifications and large-scale production makes them a key partner in the genomics and diagnostics sectors.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BZ Oligo.